ALSO NOTED: MedImmune appoints new SVP; Merck drug gets HealthCanada nod;

> MedImmune shuffled its management team last week: Andrew Skibo joined the company as senior vice president for engineering, and Dr. JoAnn Suzich was promoted to vice president of R&D-infectious disease. Release

> Health Canada gave the go-ahead to Merck's diabetes drug Januvia as an add-on treatment to metformin therapy. Report

> MGI Pharma is asking the FDA to allow it to sell a capsule form of Aloxi, an injectable drug used to treat nausea and vomiting in cancer patients. Report

> Teva Pharmaceutical Industries got the FDA nod for its generic version of DuoNeb, a bronchodilator marketed by Dey. Report

> The FDA gave its blessing to a new formulation of Sciele Pharma's high blood pressure treatment Sular. Report

And Finally... You've read our trends and predictions for the pharma industry. Now take a look back at the biotech industry in 2007 and find out what to expect in 2008. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.